APA (7th ed.) Citation

Vuylsteke, P., Huizing, M., Petrakova, K., Roylance, R., Laing, R., Chan, S., . . . Fehrenbacher, L. (2016). Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: Interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study. Annals of Oncology, 27(11), 2059. https://doi.org/10.1093/annonc/mdw320

Chicago Style (17th ed.) Citation

Vuylsteke, P., et al. "Pictilisib PI3Kinase Inhibitor (a Phosphatidylinositol 3-kinase [PI3K] Inhibitor) Plus Paclitaxel for the Treatment of Hormone Receptor-positive, HER2-negative, Locally Recurrent, or Metastatic Breast Cancer: Interim Analysis of the Multicentre, Placebo-controlled, Phase II Randomised PEGGY Study." Annals of Oncology 27, no. 11 (2016): 2059. https://doi.org/10.1093/annonc/mdw320.

MLA (9th ed.) Citation

Vuylsteke, P., et al. "Pictilisib PI3Kinase Inhibitor (a Phosphatidylinositol 3-kinase [PI3K] Inhibitor) Plus Paclitaxel for the Treatment of Hormone Receptor-positive, HER2-negative, Locally Recurrent, or Metastatic Breast Cancer: Interim Analysis of the Multicentre, Placebo-controlled, Phase II Randomised PEGGY Study." Annals of Oncology, vol. 27, no. 11, 2016, p. 2059, https://doi.org/10.1093/annonc/mdw320.